Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06624878
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-01
Brief Title:
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Intraoperative Esketamine for Prevention of Depressive Symptoms After Cytoreductive Surgery in Ovarian Cancer a Controlled Randomized Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer The main questions it aims to answer are
Whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer
Whether a single low dose of esketamine administered would relief the postoperative sleep disturbance postoperative recovery Researchers will compare the esketamine to a placebo normal saline to see if the esketamine works to reduce the postoperative depressive symptoms
Participants will
Receive either 02 mgkg esketamine or placebo infused intravenously after induction of general anesthesia
The preoperative Patient Health Questionnaire 9 PHQ-9 scale was used to verify the symptoms suggestive of depression
Whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer
Whether a single low dose of esketamine administered would relief the postoperative sleep disturbance postoperative recovery Researchers will compare the esketamine to a placebo normal saline to see if the esketamine works to reduce the postoperative depressive symptoms
Participants will
Receive either 02 mgkg esketamine or placebo infused intravenously after induction of general anesthesia
The preoperative Patient Health Questionnaire 9 PHQ-9 scale was used to verify the symptoms suggestive of depression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None